Langhorne, Pennsylvania, USA, April 7, 2026
MHRA Acceptance Marks Key Regulatory Milestone
In a significant advancement for rare disease drug development, Savara Inc. has announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Marketing Authorisation Application (MAA) for MOLBREEVI® (molgramostim inhalation solution) for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
The application has been granted Accelerated Review status, enabling a 150-day assessment timeline, with a regulatory decision expected in Q4 2026. This milestone follows prior acceptance and validation by the U.S. FDA and European Medicines Agency (EMA), placing MOLBREEVI under simultaneous regulatory review across major global markets. The coordinated regulatory progress highlights the therapy’s potential to address a critical unmet medical need in a rare and life-threatening respiratory condition.
First-in-Class Therapy Targets Rare Lung Disease
MOLBREEVI is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) designed to restore the function of alveolar macrophages, which are impaired in autoimmune PAP due to autoantibodies neutralizing GM-CSF activity. This dysfunction leads to the accumulation of surfactant in the lungs, causing breathing difficulties, reduced oxygen exchange, and progressive lung damage. Delivered via a proprietary eFlow® nebulizer system, MOLBREEVI offers a targeted inhalation therapy approach, directly addressing the underlying disease mechanism.
Advertisement
The therapy has received multiple regulatory designations, including Fast Track and Breakthrough Therapy designation from the FDA, as well as Orphan Drug designation from both the FDA and EMA, alongside Innovation Passport and Promising Innovative Medicine status from the MHRA. These recognitions underscore its potential as a first-in-class treatment for autoimmune PAP, a condition with limited or no approved pharmacological options.
Global Regulatory Momentum Strengthens Approval Outlook
Savara’s regulatory strategy demonstrates strong global alignment, with MOLBREEVI currently under Priority Review by the FDA, with a PDUFA target date of August 22, 2026, and ongoing review by the EMA’s Committee for Medicinal Products for Human Use (CHMP), with a decision anticipated in Q1 2027. The simultaneous progression across the U.S., EU, and U.K. regulatory pathways reflects both the robust clinical data package and the urgent need for innovative therapies in autoimmune PAP.
Company leadership emphasized that these milestones bring MOLBREEVI closer to becoming a globally available treatment, potentially transforming care for patients suffering from this rare disease. The accelerated timelines also highlight the importance of regulatory innovation frameworks in expediting access to life-saving therapies.
Addressing Unmet Needs in Rare Respiratory Diseases
Autoimmune PAP is a chronic and potentially life-threatening lung disorder, characterized by progressive accumulation of surfactant in the alveoli, leading to respiratory impairment and increased risk of complications such as lung fibrosis and infections. Current treatment options are limited, often involving invasive procedures such as whole lung lavage, which provide only temporary relief. MOLBREEVI’s mechanism-driven approach represents a paradigm shift toward disease-modifying therapy, targeting the root cause rather than symptoms.
As Savara advances toward potential regulatory approvals, MOLBREEVI could become a landmark therapy in rare pulmonary medicine, improving both clinical outcomes and quality of life for patients worldwide. This development underscores the growing importance of precision biologics and targeted inhalation therapies in addressing complex respiratory diseases and advancing the future of pharmaceutical innovation.
Source: Savara press release
